Clinical, pathologic, and molecular features of amphicrine prostate cancer

Amphicrine prostate carcinoma (AMPC) is a poorly defined subset of prostate cancer in which cells co‐express luminal prostate epithelial and neuroendocrine markers. The optimal treatment strategy is unknown. We sought to further characterize the clinical, histomorphologic, and molecular characteristics of AMPC and to identify areas of potential future treatment investigations.

[1]  V. Reuter,et al.  Neuroendocrine differentiation in the setting of prostatic carcinoma: contemporary assessment of a consecutive series , 2022, Histopathology.

[2]  D. Rickman,et al.  RNA Splicing Factors SRRM3 and SRRM4 Distinguish Molecular Phenotypes of Castration-Resistant Neuroendocrine Prostate Cancer , 2021, Cancer Research.

[3]  A. Chinnaiyan,et al.  De novo neuroendocrine transdifferentiation in primary prostate cancer–a phenotype associated with advanced clinico-pathologic features and aggressive outcome , 2021, Medical Oncology.

[4]  H. Beltran,et al.  Clinical and Biological Features of Neuroendocrine Prostate Cancer , 2021, Current Oncology Reports.

[5]  C. Pritchard,et al.  Validation and implementation of a modular targeted capture assay for the detection of clinically significant molecular oncology alterations , 2020, Practical laboratory medicine.

[6]  P. Nelson,et al.  Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer. , 2019, The Journal of clinical investigation.

[7]  Yi Mi Wu,et al.  Genomic correlates of clinical outcome in advanced prostate cancer , 2019, Proceedings of the National Academy of Sciences.

[8]  Joshua M. Stuart,et al.  Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  A. Evans,et al.  Prostate carcinoma with amphicrine features: further refining the spectrum of neuroendocrine differentiation in tumours of primary prostatic origin? , 2017, Histopathology.

[10]  Michael D. Nyquist,et al.  Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling. , 2017, Cancer cell.

[11]  M. Schweizer,et al.  Targeting persistent androgen receptor signaling in castration-resistant prostate cancer , 2016, Medical Oncology.

[12]  P. Nelson,et al.  Characterizing the molecular features of ERG‐positive tumors in primary and castration resistant prostate cancer , 2016, The Prostate.

[13]  Steven J. M. Jones,et al.  The Molecular Taxonomy of Primary Prostate Cancer , 2015, Cell.

[14]  J. Reifenrath,et al.  Different approaches for interpretation and reporting of immunohistochemistry analysis results in the bone tissue – a review , 2014, Diagnostic Pathology.

[15]  Jiao Zhang,et al.  Neuroendocrine Prostate Cancer (NEPC) progressing from conventional prostatic adenocarcinoma: factors associated with time to development of NEPC and survival from NEPC diagnosis-a systematic review and pooled analysis. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  M. Rubin,et al.  Proposed Morphologic Classification of Prostate Cancer With Neuroendocrine Differentiation , 2014, The American journal of surgical pathology.

[17]  J. Epstein,et al.  Small cell carcinoma of the prostate , 2014, Nature Reviews Urology.

[18]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[19]  Justin Guinney,et al.  GSVA: gene set variation analysis for microarray and RNA-Seq data , 2013, BMC Bioinformatics.